Skip to main content
Up to 53% offSee the plans

Back to articles | Analysis | Stocks

Loghman Pharmaceutical Trades Below the Drug Sector, but Its Half-Year Profit Has Not Yet Reached the Bank (Sunday 22 November 2026)

Sahmino Research Desk | 22 November 2026 | 8 min read

Loghman Pharmaceutical & Hygienic (DLGM) closed at 10,910 rials on 22 November 2026, a P/E of 7.35 against 11.45 for the drug sector. Audited six-month net profit was 12,104 billion rials, 3.6 times a year earlier and above all of fiscal 1404, but operating cash flow was minus 6,016 billion rials and receivables rose 79%. October sales beat the…
DLGMup2.9%10,910rials22 November

Related video

Watch the full video

Loghman Pharmaceutical & Hygienic (symbol DLGM) closed Sunday's session, 22 November 2026 (1 Azar 1405), at 10,910 rials with a buy queue at the top of its daily band (read at 17:30 Tehran time). On the 1,485-rial earnings per share the exchange publishes for the stock, that is a price-to-earnings ratio of 7.35, while the same ratio for the "pharmaceutical materials and products" group is 11.45: roughly 36% below the sector. The question this piece answers is simple: is that discount an opportunity or a trap?

The answer sits in two financial statements and one monthly report the company filed on Codal: profit really has jumped and the auditor has signed it, but a large part of it is still on the balance sheet as money owed by customers.

Background

The stock has multiplied over the past year: its lowest traded price in the last 52 weeks was 2,770 rials on 23 November 2025 and its highest was 11,590 rials on 23 August 2026. Since then, for about three months, it has moved sideways in a channel between a lowest close of 8,920 rials (21 September) and 11,590 rials. Two versions of the half-year statements came out in that window: the unaudited one on 22 October and the audited one on 19 November. In other words, the half-year profit arrived after the price peak, and the price has not yet returned to that peak.

The pattern is not unique in the drug sector; Sahmino has also written about Farabi Pharmaceutical's profit and operating cash and Zahravi Pharmaceutical's six-month profit jump.

The numbers

Codal prints these amounts in millions of rials; they are rounded here to billions of rials. All figures are from the company's standalone statements for the six months to 22 September 2026 (Codal tracing number 1633287, audited).

  • Operating revenue: 28,189 billion rials against 10,297 billion rials a year earlier, up 174%.
  • Gross profit: 17,575 billion rials against 2,988; gross margin rose from 29.0% to 62.3%.
  • Operating profit: 16,464 billion rials against 2,416.
  • Finance costs: 1,729 billion rials against 610, or 2.8 times.
  • Net profit: 12,104 billion rials against 3,383 billion rials, 3.6 times (up 258%), and 1.87 times the whole of fiscal 1404 (6,474 billion rials). Six-month EPS was 1,183 rials against 330.
  • The auditor nudged the figure up: net profit in the unaudited version of 22 October (tracing number 1609461) was 12,095 billion rials, and revenue is identical in both.

The other half of the picture is in the cash flow statement and the balance sheet:

  • Net operating cash flow for the six months was minus 6,016 billion rials (minus 2,069 a year earlier).
  • Trade and other receivables rose from 17,873 billion rials on 20 March 2026 to 31,936 billion rials on 22 September, up 79%; inventories doubled from 4,549 to 9,130 billion rials.
  • The company drew 16,155 billion rials of bank facilities in the six months and repaid 5,863 billion; net new borrowing was 10,292 billion rials. Interest-bearing debt at the end of the period was 13,728 billion rials and cash 5,303 billion rials.
  • Dividends payable stand at 3,512 billion rials; the 12 July 2026 annual meeting approved a cash dividend of 316 rials a share for fiscal 1404 (50% of EPS of 632 rials).

And the monthly activity report for Mehr 1405, the month to 22 October 2026 (tracing number 1620582): net sales after returns and discounts were 5,545 billion rials, above the 4,698-billion-rial monthly average of the first six months. Seven-month sales reached 33,735 billion rials, 2.56 times the 13,179 billion rials of the same seven months a year earlier. The six-month total in that monthly report, 28,189 billion rials, matches the revenue line of the income statement.

Drivers

The mechanism shows in the monthly report itself: growth came from prices, not volumes. Over seven months, the number of vials sold fell from 34,201 units to 20,509 units, but the average price per vial unit rose 3.4 times; tablets sold were 10% fewer while their average price doubled. Because cost of sales rose only 45% against 174% for revenue, the gross margin more than doubled. The cost of that growth sits on the balance sheet: higher sales came with more money owed by buyers, and the company bridged the gap with bank loans, which is what the 2.8-fold finance cost reflects. The ratio of operating cash to profit is the measure that exposes this gap.

Money flows are mixed too. Over the 20 sessions to 21 November, individual investors were net sellers of about 1,127 billion rials in total, but on 22 November they were net buyers of about 2.7 million shares, with an individual buyer-strength reading of 2.03. Sahmino's desk held a "watch" stance on the stock in the 21 November session and set no target or invalidation; the closing reading in this piece is built from the evidence shown here.

Outlook

Two stories compete. The trap story says profit that is not collected and is backed by loans is worth less, and the market is right to pay a lower multiple for it. The opportunity story says monthly sales stayed high after September, the auditor confirmed the figure and the company's cash also rose 120%, so the issue is the speed of collection, not whether the sales are real. Today's data tips the balance towards the second, provided sales in the coming months do not fall. The next signal is the Aban monthly report, which by the usual timetable is filed in the first weeks of Azar (late November to mid December). The DLGM page on Sahmino shows the price, individual and institutional flows and the P/E daily.

Conclusion

Our reading: Loghman Pharmaceutical's discount to its sector is more the price of waiting for collections than a sign of a trap, because both the audited profit and monthly sales confirm the growth. Loghman Pharmaceutical returns to 11,590 rials, its 23 August peak, by the end of Azar 1405 (21 December 2026), provided Aban monthly sales do not fall below October's 5,545 billion rials. A close below 9,630 rials, the 14 November close, invalidates this reading (basis: the 22 November 2026 close of 10,910 rials).

What to watch

  • Net sales for Aban in the monthly activity report, against October's 5,545 billion rials.
  • Receivables and operating cash flow in the nine-month statements.
  • Interest-bearing debt and finance costs, which rise with every month of delayed collection.
  • Find similar stocks in Sahmino's screener: P/E below 80% of the sector, annual profit growth above 50%, a three-month return below 10%, debt to equity below one and a 20-day average traded value above 20 billion rials; on 22 November 2026 six stocks passed this filter, DLGM among them.

Terms

  • Price-to-earnings ratio: the share price divided by annual earnings per share; the lower it is, the less the market pays for each rial of profit.
  • Operating cash flow: the money the company actually received from its core business, not the profit recorded on paper.
  • Receivables: what buyers who have taken delivery still owe the company.

References

  1. CodalAudited six-month income statement to 22 Sep 2026 (tracing 1633287): net profit 12,104,341 million rials vs 3,382,542; operating cash flow minus 6,016,237 million rialsCited Nov 22, 2026
  2. CodalMonthly activity report for the month to 22 Oct 2026 (tracing 1620582): net sales 5,545,263 million rials; seven months 33,734,607 million rialsCited Nov 22, 2026
  3. SahminoDLGM: close 10,910 rials on 22 Nov 2026; P/E 7.35 vs pharmaceutical group 11.45Cited Nov 22, 2026

Related articles